FUTURE OF HEALTHCARE
Rockley Photonics | March 11, 2022
Rockley Photonics Holdings Limited a global leader in photonics-based health monitoring and communications solutions, announced that it has agreed to enter a development partnership with Medtronic, a global leader in healthcare technology. The two companies plan to collaborate to bring Rockley’s recently announced Bioptx™ biomarker sensing platform into Medtronic’s solutions for use across various healthcare settings.
Rockley’s biosensing technology is expected to expand the capabilities of wearable medtech devices by miniaturizing the measurement and analysis of a range of biomarkers into a compact form factor. These advances mean that a single wearable device could monitor multiple crucial biomarkers – including core body temperature, blood pressure, body hydration, alcohol, lactate, and glucose trends, among others. The Bioptx platform offers an end-to-end sensing solution that integrates cloud analytics and artificial intelligence (AI) to potentially deliver a holistic assessment of a variety of conditions.
The partnership with Medtronic builds on the societal shift from reactive to proactive healthcare by potentially enabling round-the-clock, real-time, non-invasive monitoring of a person’s health and well-being, thereby empowering clinicians to personalize care with actionable data.
“This partnership combines Medtronic’s exceptional strength in providing in-patient care with Rockley’s expertise in wearable, remote monitoring. I believe that this collaboration will bring to life our vision of giving people better insights into their health and well-being. We are excited about the potential for this partnership to herald the next generation of wearable devices and deliver a complete lifecycle of patient care.”
Dr. Andrew Rickman, chairman and chief executive officer of Rockley
About Rockley Photonics
A global leader in photonics-based health monitoring and communications solutions, Rockley Photonics is developing a comprehensive range of photonic integrated circuits and associated modules, sensors, and full-stack solutions. From next-generation sensing platforms specifically designed for mobile health monitoring and machine vision to high-speed, high-volume solutions for data communications, Rockley is laying the foundation for a new generation of applications across multiple industries. Rockley believes that photonics will eventually become as pervasive as micro-electronics, and it has developed a platform with the power and flexibility needed to address both mass markets and a wide variety of vertical applications.
UniDoc | February 04, 2022
UniDoc Health Corp., an innovator in the telehealth sector, is pleased to advise on a commercial master distribution agreement (the “Agreement”) with Massachusetts-based AMD Global Telemedicine Inc. (“AMD Global”) for the provision of specialized products and services critical to ongoing commercialization efforts.
As a pioneer of virtual care technology, and an industry leader in telehealth solutions, AMD Global has been providing quality healthcare solutions for over 30 years with product sales and registered deployments in 100+ countries. The agreement adds AMD Global as a UniDoc key supplier of telehealth solutions including virtual care software platforms, integrated medical devices, and telemedicine bundled kits.
The products and services will be purposed and integrated into the UniDoc Virtual Care Solutions Model (“VCSM”), which will offer a proprietary, customizable, and comprehensive telehealth solution based on a variety of integrated physical enclosures, kiosks, and related configurable packaging designed to deliver web-based services and analytical tools in combination with access to a developing network of healthcare providers, pharmacies, and hospitals.
All AMD Global products and telehealth technologies are built to provide high performance and quality, are easy to use and maintain, and operate dependably even in difficult environments. AMD Global is ISO 13485:2003 certified and runs an FDA registered facility operating within good manufacturing telemedicine best practices guidelines. The AMD platform provides UniDoc with immediate access to FDA & Health Canada approved devices (FDA Certified; ISO 13485; and FDA GMP – including all HIPPAA privacy and compliance) which support and help propel the Company’s fast-track plans for commercialization.
Mr. Eric Bacon, President of AMD Global Telemedicine Inc. states, we are very pleased to have this opportunity to work with the UniDoc team. Their dedication, passion and commitment are outstanding and adds great value to their ability to drive ahead, overcome obstacles, and keep focused on achieving results. Their offering is unique in its vision and feasibility to scale. We are excited to have been chosen as UniDoc’s provider of choice for their telehealth technology needs today as well as help them extend and develop their telehealth portfolio going forward.”
“We are so very delighted to have this opportunity to work with AMD Global as a key vendor of critical components and services. When we began this venture, we found a very short list of suppliers who so clearly fit our needs and timelines. It didn’t take long to determine that AMD’s medical grade instruments are integrated into high quality software. Additionally, AMD completely met our needs when it came to ensuring all required certification and compliance requirements were already in place. To everyone’s credit on both sides, the synergies were readily apparent, and it didn’t take long to come to an agreement. I’m confident that this arrangement will prove instrumental in unlocking the value of this exciting venture together.”
UniDoc CEO Antonio Baldassarre
About UniDoc Health Corp.
UniDoc is developing a telehealth solution which is being designed as a self-contained remote virtual clinic within a private kiosk for patients to undergo full consultations as if they were present in a physician’s office. Telehealth opens the doors to a large segment of the population challenged by access, experience or understanding of online computer technology. It is the Company’s belief that physical accessibility is the key to its business proposition. UniDoc is dedicated to unlocking shareholder value by delivering an excellent product and sophisticated commercial network within an expedited timeframe.
Northwell Health | April 13, 2022
Northwell Health, New York’s largest healthcare provider, and Aegis Ventures, a New York-based startup studio announced at their inaugural Healthcare AI Innovation Summit the finalization of definitive agreements to launch Ascertain, a joint company creation platform. Ascertain is a first-of-its-kind partnership that pairs a dynamic venture studio with one of the nation’s largest and most impactful health systems to develop and commercialize breakthrough healthcare AI companies that improve quality and access to care and close health equity gaps.
Ascertain represents a novel, more targeted approach to the way entrepreneurs and healthcare systems collaborate to solve major healthcare challenges. The platform combines clinical and business leadership, expert technical and product teams, access to Northwell’s leading, diverse datasets, and capital resources within a single ecosystem – with a sole focus on building and validating effective solutions that can be rapidly brought to market.
“Ascertain brings a unique structure, an innovative approach, and a compelling vision to create breakthrough healthcare AI companies that are set up for success. We are all driven by the idea that everyone deserves access to high-quality, affordable healthcare. Our aim is clear: to find new, cost-efficient ways to create and accelerate companies that deliver real, equitable solutions.”
Michael Dowling, President and CEO of Northwell Health
Ascertain has commenced the creation of its first portfolio companies in partnership with Northwell’s clinicians and administrators. One such collaboration is focused on bringing substantive improvements in maternal health, working hand-in-hand with Northwell’s recently launched Center for Maternal Health to develop new approaches to detecting and managing serious complications for expectant mothers and babies. Ascertain’s data science team has been working hand-in-hand with Northwell’s Maternal and Fetal Medicine team to examine tens of thousands of cases of preeclampsia, a hypertensive pregnancy complication that disproportionately affects Black mothers in the United States.
Using cutting-edge data science techniques, the Ascertain team aims to deliver an AI solution that helps clinicians predict the risk of developing preeclampsia, enabling them to intervene earlier than previously possible.
“Existing approaches to the detection of preeclampsia often occur too late in pregnancy, once the condition has begun to manifest. An important enabler for a solution to this challenge is predictive analytics, applying available knowledge of a patient's history to enable action far earlier with simple, yet life-saving, clinical interventions. We believe the AI solution Ascertain is currently developing will enable this,” shared Burt Rochelson, MD, Chief of Maternal Medicine at Northwell Health.
“Aegis and Northwell’s multidisciplinary teams are pursuing innovation through a systematic approach that will bring validated solutions to patients more quickly and at a lower cost,” said Bill Schoenfeld, Aegis Ventures Chairman. “Our skillsets are extraordinarily complementary and enable us to address healthcare’s most entrenched quality, equity, and cost problems far more powerfully than either organization could alone.”
Ascertain is preparing to launch multiple companies in 2022 that focus on maternal health, chronic disease detection and management, and next-generation AI tools.
Ascertain’s Chairman Tom Manning shared, “Together, we’re paving a new way forward, a monumental step toward real, proven AI solutions that can bring impact to the world. It is a bold collaboration to drive AI-backed companies that save lives and resolve long-standing health inequities – and realize results that deliver something greater in healthcare.”
Ascertain is committed to building exceptional teams that will embrace this unique opportunity to create unparalleled impact. To learn more about Ascertain or register your interest, please visit https://ascertain.com/.
Ascertain is a revolutionary new partnership between Northwell Health, New York’s largest healthcare provider, and Aegis Ventures, a dynamic startup studio. This unique partnership assembles leading medical, technology, and business resources to create a first-of-its-kind company creation platform for healthcare innovation to address healthcare’s most challenging quality, equity, and cost problems. Ascertain brings $100M in seed-stage capital to bear in pursuit of a three-pronged approach to company creation: internal ideation, commercialization of scientific breakthroughs, and US market entry partnerships for global ventures. Ascertain creates companies that improve quality of care, patient experience, and long-standing health, placing patient needs at the center of every business model, technology solution, and product.
About Northwell Health
Northwell Health is New York State’s largest healthcare provider and private employer, with 23 hospitals, 830 outpatient facilities and more than 16,600 affiliated physicians. We care for over two million people annually in the New York metro area and beyond, thanks to philanthropic support from our communities. Our 77,000 employees – 18,900 nurses and 4,800 employed doctors, including members of Northwell Health Physician Partners – are working to change healthcare for the better. We’re making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We're training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Nursing and Physician Assistant Studies.
About Aegis Ventures
Aegis Ventures is a next-generation startup studio that partners with entrepreneurs and industry leaders to originate, launch, and scale transformative companies. Our platform brings together market-shaping ideas, permanent growth capital, and ambitious individuals driven to solve major societal problems. We aim to build companies with the capacity for vast impact, with an initial focus on artificial intelligence and digital health. Within these verticals, Aegis seeks to create companies that leverage technology to better optimize tradeoffs between quality, access, and cost, focusing on innovations that promote seamless continuity of care, patient empowerment, and better-informed clinical decision-making.
Purpose Investments | January 19, 2022
Purpose Investments Inc. (“Purpose Investments” or “Purpose”) is pleased to announce the launch of Purpose Healthcare Innovation Yield ETF (the “Fund”). The Fund has closed the offering of its initial units, and units of the Fund will begin trading today on the Toronto Stock Exchange under the ticker, HEAL.
The Fund is the first of its kind in Canada to provide actively managed exposure to innovation leaders in biotech and healthcare. The recent advances in healthcare are only the beginning of what Purpose believes to be a new multi-year cycle in biotech and healthcare breakthroughs that will provide investors with opportunity for attractive long-term returns. The Fund will invest in an all-cap portfolio in the high-growth areas of gene-editing, digital healthcare, medical testing, dental, health maintenance, hospitals, pharmacies, and animal health. The portfolio holdings are primed for long-term growth and armed with commercialization opportunities and a strong pipeline of products under development. The Fund will also employ a covered call options strategy to generate additional yield and will have a more attractive income profile than the broad healthcare index.
“The past two years have shown just how important it is to have innovative companies develop vaccines and push forward medical advancements. Between the pandemic and our aging population, the spotlight is on the industry to really grow and innovate. We launched this Fund to give Canadians an opportunity to get actively managed exposure to the healthcare companies that are changing the world with cutting-edge medical and technological advancements.”
Som Seif, founder and CEO of Purpose Investments
Purpose is the manager of the Fund and Next Edge Capital Corp. (“Next Edge Capital”) will act as the Fund’s sub-advisor. The Fund will be actively managed by Eden Rahimof Next Edge Capital, one of the world’s leading experts in healthcare investing. Mr. Rahim has an academic background in molecular genetics and extensive experience managing life-science and biotech portfolios. His active management, informed by his science background and industry experience, will position the Fund to capitalize on high-growth opportunities in the biotech and healthcare sectors.
“With this Fund, we will work to strategically identify key healthcare companies developing innovations that will profoundly improve people’s lives,” says Rahim. “Purpose Healthcare Innovation Yield ETF aims to provide investors with exposure to unique opportunities that may not be on their radar, so they can reap the full rewards of the high-growth areas in healthcare and science.”
“Eden is one of the leading global experts in healthcare investing, and someone who understands the math as well as the science backing the portfolio. We are excited to have such a seasoned portfolio manager help us maximize the growth opportunities in the space and provide investors with a strategy to generate attractive yield,” Seif concluded.
About Purpose Investments
Purpose Investments Inc. is an asset management company with approximately $14 billion in assets under management. Purpose has an unrelenting focus on client-centric innovation, and offers a range of outcome-focused products. Purpose Investments is led by well-known entrepreneur Som Seif and is a division of Purpose Financial, an independent technology-driven financial services company.